Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment

Spero Therapeutics Inc SPRO initiated two Phase 1 trials of SPR206, including bronchoalveolar lavage (BAL) trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment trial.
The Phase 1 BAL trial will enroll 30 healthy volunteers into five cohorts. Subjects will receive three 100 mg doses of SPR206 infused every eight hours over one day.
The study's objectives are to evaluate the intrapulmonary PK, including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR206 compared to plasma concentrations.
The trial initiation has triggered the first of two milestone payments related to the study from Spero's development partner, Everest Medicines.
The Phase 1 renal impairment trial will enroll 40 subjects into five cohorts.
Subjects will receive a single 100 mg infusion of SPR206.
The study's objectives are to evaluate the PK of SPR206 in healthy subjects and those with various degrees of renal insufficiency, including end-stage renal disease.
Results from the clinical trials are expected by early 2022.
The U.S. Department of Defense is providing financial support for both trials.
SPR206 is an IV-administered next-generation polymyxin candidate designed to act directly on Gram-negative bacterial infections.
Price Action: SPRO shares closed at $15.24 on Tuesday.